Skip to main content
. 2022 Aug 21;71(8):1735–1745. doi: 10.2337/db21-1069

Figure 4.

Figure 4

Ab-2.5HIP treatment leads to reduced diabetes incidence in a BDC2.5 thymus transplant model. A: Thymus transplant experimental design. B: Diabetes incidence of the thymus transplant recipients (n = 9 per group). C: Insulitis evaluation of thymus transplant recipients at 2 weeks posttransplant (insulitis score: 0 = no infiltrates, 1 = peri-islet infiltrates, 2 = intraislet infiltrates to ≤50%, 3 = intraislet infiltrates to ≥50%; n = 5–6 per group; data from two independent experiments). D: Quantification of donor CD4 T-cell percentage in the spleen, aLN, and pLN 2 weeks after thymus transplant (n = 6 per group). E: Representative flow plot and quantification of Foxp3+ cell percentage in the spleen, aLN, and pLN 2 weeks after thymus transplant (n = 5–6 per group). Data are reported as mean ± SD. Mann-Whitney U test (C–E) and Gehan-Breslow-Wilcoxon test (E). *P < 0.05, **P < 0.01, ***P < 0.001.